Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.

ABSTRACT:

Background

Biologic therapies in patients with Crohn's disease often yield low clinical and endoscopic remission rates. After multiple failed therapies, combining two biologic therapies is possibly the sole medical alternative to recurrent surgery. However, data on this approach are limited.

Aims

To assess the efficacy and safety of concomitant use of two biologic therapies in the largest cohort to date of refractory Crohn's disease patients.

Methods

Data were extracted from Crohn's disease patients started on dual biologic therapy at two referral centres. Biologics utilised include infliximab, adalimumab, vedolizumab, ustekinumab, certolizumab and golimumab. The primary outcome was endoscopic improvement (>50% reduction in Simplified Endoscopic Score-Crohn's disease

SUBMITTER: Yang E 

PROVIDER: S-EPMC8032452 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature